New analysis suggests that people with type 2 diabetes taking GLP-1 drugs such as Ozempic, Trulicity or Victoza are less likely to develop epilepsy compared to those taking DPP-4 inhibitors. Semaglutide showed the strongest association with reduced risk of epilepsy. The researchers emphasize that the findings only show an association, not proof of cause and effect. More rigorous longitudinal studies are needed to better understand this link. Ozempic may thus offer a surprising bonus benefit for brain health.